Three-Year Outcomes Following Permissive Cardiotoxicity in Patients on Trastuzumab

INTRODUCTION: Cardiotoxicity, manifest by reduced left ventricular ejection fraction (LVEF), is the most common reason for the premature discontinuation of trastuzumab. While permissive cardiotoxicity (where mild cardiotoxicity is accepted to enable ongoing trastuzumab) has been shown feasible, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Shijie, Cirne, Filipe, Chow, Justin, Zereshkian, Arman, Bordeleau, Louise, Dhesy-Thind, Sukhbinder, Ellis, Peter M, Mukherjee, Som D, Aghel, Nazanin, Leong, Darryl P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Breast Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485282/
https://www.ncbi.nlm.nih.gov/pubmed/37094996
http://dx.doi.org/10.1093/oncolo/oyad086

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485282/
https://www.ncbi.nlm.nih.gov/pubmed/37094996
http://dx.doi.org/10.1093/oncolo/oyad086

Ejemplares similares